American journal of ophthalmology
Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study.
Yuichi Hori, Tomoyuki Wada, Kazunori Omatsu, SJP-0132 clinical study investigators
Published: 202510.1016/j.ajo.2025.11.036
Abstract
OBJECTIVE: Evaluate the efficacy, safety, and optimal dose of the TRPV1 antagonist SJP-0132 ophthalmic suspension in patients with dry eye disease. DESIGN: Randomized, double-masked, multicenter, placebo-controlled, Phase 2b dose-response study in Ja…
Preview only. Read the full abstract at the source